Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
02:19pm, Wednesday, 06'th Aug 2025
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop fundi
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish
09:33am, Monday, 04'th Aug 2025
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. MRNA stock has plummeted over 70% in the past year, reflecting in
Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings
07:01pm, Friday, 01'st Aug 2025
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street e
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
04:51pm, Friday, 01'st Aug 2025
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
02:26pm, Friday, 01'st Aug 2025
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
11:56am, Friday, 01'st Aug 2025
Moderna, Inc. (NASDAQ:MRNA ) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Rela
Moderna slashes full-year sales outlook, reduces headcount
11:23am, Friday, 01'st Aug 2025
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares fell almost 9% in early trade as the pharmaceutical giant lowered its full-year guidance and announced a workforce reduction, overshadowing a Q2 earnings beat
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
11:10am, Friday, 01'st Aug 2025
Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
Moderna cuts 2025 revenue to $2.2B after UK booster delay
10:11am, Friday, 01'st Aug 2025
Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
09:11am, Friday, 01'st Aug 2025
Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago.
Moderna is laying off 10% of its workforce. Does RFK Jr. have anything to do with it?
08:40am, Friday, 01'st Aug 2025
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
Moderna Stock Drops After Earnings Report. What Has Wall Street Worried.
07:23am, Friday, 01'st Aug 2025
Moderna stock was falling in Friday's premarket after the drugmaker's better-than-expected quarterly results were overshadowed by a cut to the high end of its full-year outlook.
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
07:08am, Friday, 01'st Aug 2025
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by robust Spring COVID booster demand and aggressive cost cuts.
Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
07:03am, Friday, 01'st Aug 2025
Moderna lowered the high end of its 2025 revenue outlook, citing a delay in vaccine shipments to the U.K. The company lost less than Wall Street analysts were expecting for the second quarter and po
